# Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

> **NCT03755154** · PHASE1 · TERMINATED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 60 (actual)

## Conditions studied

- Relapsed or Refractory Acute Myeloid Leukemia
- Relapsed or Refractory Non-Hodgkin Lymphoma
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** S65487- initial scheme
- **DRUG:** S65487 - alternative scheme

## Key facts

- **NCT ID:** NCT03755154
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-17
- **Primary completion:** 2023-11-06
- **Final completion:** 2023-11-06
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** The study was prematurely terminated on 14th March 2023 for strategic considerations due to the limited efficacy seen with this treatment in monotherapy. This decision was not based on any safety concerns.
- **Last updated:** 2024-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03755154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03755154, "Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03755154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*